# Sirolimus Prophylaxis for aGVHD in TME SCID

> **NCT02177760** · PHASE2 · WITHDRAWN · sponsor: **University of California, San Francisco**

## Conditions studied

- Severe Combined Immunodeficiency
- Transplacental Maternal Engraftment
- Stem Cell Transplant

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT02177760
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-07
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Preliminary data suggested a better approach available
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02177760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02177760, "Sirolimus Prophylaxis for aGVHD in TME SCID". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02177760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*